iShares MSCI Japan ETF vs 10X Genomics Inc — how do they compare? iShares MSCI Japan ETF trades at $97.42 (market cap $23.87B), while 10X Genomics Inc trades at $79 (market cap $10.07B). The key difference: iShares MSCI Japan ETF is far larger — about 2.4× 10X Genomics Inc's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and 10X Genomics Inc for 92 Days on average.
| EWJ | TXG | |
|---|---|---|
Market Cap | $23.87B | $10.07B |
Volume | 5,412,820 | 5,657,286 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $97.74 |
52-Week Low | $78.36 | $11.48 |
Typical Hold Time | 56 Days | 92 Days |
Enterprise Value | — | $9.59B |
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $98.32, down 1.01% on the day amid broader Asian market pressures. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. Recent news highlights Japan's monetary policy shifts with BOJ rate hikes and yen volatility creating both opportunities and challenges for Japanese equities. The ETF has demonstrated strong performance in 2026, outperforming the S&P 500 with gains exceeding 20% according to Zacks Investment Research (September 30, 2026).
The outlook for EWJ remains constructive given Japan's economic reforms and AI sector growth, though rising bond yields and currency fluctuations present near-term headwinds. Institutional interest appears strong as Japan's market rotation toward technology and AI plays supports continued ETF inflows. Key risks include BOJ policy uncertainty and global interest rate dynamics that could pressure Japanese equities.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →